This section covers advanced and emerging approaches to speech and communication therapy for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Building upon the foundational speech-language intervention principles in Section 113: Speech and Language Therapy, this advanced section explores cutting-edge therapeutic modalities, intensive treatment protocols, technological augmentations, and emerging interventions that represent the frontier of speech-language pathology for atypical parkinsonian disorders.
The rationale for advanced interventions stems from the progressive nature of CBS and PSP, the inadequate response to standard speech therapy protocols in many patients, and the rapidly evolving landscape of assistive communication technology and neuromodulation approaches[1].
While the standard LSVT LOUD protocol (4 sessions/week for 4 weeks) demonstrates efficacy, emerging evidence supports extended or intensive protocols for patients with atypical parkinsonism who may require more intensive intervention to achieve benefits.
Extended Protocol Options:
| Protocol | Duration | Intensity | Evidence Level | Target Population |
|---|---|---|---|---|
| Standard LSVT LOUD | 4 weeks | 4x/week | Strong | Early CBS/PSP |
| Extended LSVT | 8-12 weeks | 3x/week | Moderate | Moderate progression |
| Intensive LSVT | 2 weeks | 2x/day | Moderate | Advanced disease, high motivation |
| Home-based intensive | 6 weeks | Daily | Moderate | Geographic barriers |
Extended Protocol Rationale:
Corticobasal syndrome presents unique challenges requiring protocol modifications:
CBS-Specific Modifications:
Fatigue Management
Asymmetric Presentation
Apraxia Integration
Progressive supranuclear palsy requires distinct protocol adaptations:
PSP-Specific Modifications:
Oculomotor Considerations
Positioning Adaptations
Bradykinesia Integration
Progressive Disease Staging
Electropalatography provides visual feedback of tongue-palate contact patterns during speech, enabling patients to see articulatory movements that are normally hidden.
EPG Applications in CBS/PSP:
Evidence and Considerations:
EPG has demonstrated efficacy in dysarthria rehabilitation, though its application in CBS/PSP requires adaptation due to the progressive nature of these conditions. Patients with cognitive impairment may have difficulty interpreting visual feedback, limiting applicability in advanced disease stages[3].
Surface electromyography provides feedback on muscle activity during speech production, enabling patients to learn to modify muscle tension and coordination.
sEMG Applications:
| Parameter | Measurement | Therapeutic Application |
|---|---|---|
| Lip muscle tension | Labial sEMG | Reduce excessive tension, improve articulatory precision |
| Laryngeal muscle activity | Thyroid cartilage sEMG | Modulate vocal intensity, reduce strain |
| Respiratory muscle coordination | Thoracic sEMG | Optimize breath support for speech |
Biofeedback Protocol:
Clinical Considerations:
sEMG biofeedback requires specialized equipment and training. It is most appropriate for patients with adequate cognitive function to interpret visual feedback and moderate motor control to modify speech production based on feedback[4].
Rate and rhythm disturbances in CBS/PSP dysarthria can be addressed through external pacing strategies.
Pacing Technologies:
| Device | Mechanism | Advantages | Limitations |
|---|---|---|---|
| Pacing board | Visual + tactile | Simple, portable, low-cost | Requires hand function |
| Metronome | Auditory rhythm | Adjustable tempo, portable | May not transfer to natural speech |
| Speech-generating device | Programmed delays | Integrated AAC, customizable | Technology barrier for some |
| Delayed auditory feedback (DAF) | Slows perceived rate | Natural speech, no manual operation | Variable tolerance |
DAF Device Settings for CBS/PSP:
| Severity | Delay Setting | Typical Improvement |
|---|---|---|
| Mild | 50-100 ms | 10-15% intelligibility gain |
| Moderate | 100-150 ms | 15-25% intelligibility gain |
| Severe | 150-200 ms | Variable response |
Modifying utterance length can significantly improve intelligibility in hypokinetic dysarthria.
Chunking Protocol:
Evidence Base:
Research demonstrates that chunking strategies can improve intelligibility by 20-30% in dysarthria, with greatest gains in moderate severity. Transfer to spontaneous conversation requires systematic practice across utterance lengths[5].
Beyond basic communication boards and tablet applications, advanced AAC systems offer enhanced functionality for patients with severe communication impairment.
Advanced AAC Platforms:
| System | Input Method | Output | Advanced Features |
|---|---|---|---|
| Grid 3 | Touch, eye gaze, scanning | Synthetic speech | Dynamic conversations, cell phones |
| Tobii Dynavox | Eye gaze | Synthetic speech | Window Eyes integration, scanning |
| Accent | Touch, keyguard | Synthetic speech | Environmental control |
| Posterior Talker | Eye gaze | Synthetic speech | Designed for ALS, adaptable to PSP |
Emerging neural interface technologies represent the frontier of augmentative communication for patients with severe motor impairment.
Current Technologies:
Electroencephalography (EEG)-Based BCIs
Electrocorticography (ECoG)-Based BCIs
Future Directions
Clinical Considerations:
BCI technology remains experimental and is not yet clinically available for CBS/PSP. However, monitoring developments is essential as these technologies may offer communication solutions when standard AAC becomes insufficient.
Preservation of the patient's own voice for future AAC use is increasingly important as speech deterioration progresses.
Voice Banking Protocol:
| Phase | Duration | Content | Technical Requirements |
|---|---|---|---|
| Recording | 2-4 hours | 1600+ phrases | Recording software, sound booth |
| Processing | Variable | Voice banking service | Online service or software |
| Integration | 1-2 hours | AAC programming | AAC device setup |
Message Banking Protocol:
Recommended Timing:
Voice banking should begin at diagnosis or earliest disease stage when speech is still normal, while the patient can actively participate in the recording process.
tDCS modulates cortical excitability and may enhance speech therapy outcomes when combined with traditional treatment.
tDCS Parameters:
| Parameter | Typical Setting | Rationale |
|---|---|---|
| Polarity | Anodal (excitatory) | Enhance speech motor cortex |
| Intensity | 1-2 mA | Safe, well-tolerated |
| Duration | 20-30 minutes | Standard protocol |
| Location | Left inferior frontal gyrus, motor cortex | Speech production areas |
| Sessions | 10-20 combined with speech therapy | Cumulative effect |
Evidence in Neurodegeneration:
tDCS combined with speech therapy has shown promise in Parkinson's disease, with limited but growing evidence in atypical parkinsonism. The combination may enhance neuroplasticity and improve speech outcomes beyond speech therapy alone[6].
rTMS provides stronger cortical modulation through magnetic induction.
rTMS Protocols:
| Protocol | Frequency | Sessions | Target |
|---|---|---|---|
| High-frequency rTMS | 5-25 Hz | 5-10 | Left IFG, bilateral M1 |
| Low-frequency rTMS | 1 Hz | 5-10 | Right IFG (for hyperactivation) |
| Theta-burst stimulation | 50 Hz | 5-10 | IFG, motor cortex |
Considerations for CBS/PSP:
Remote delivery of speech-language services has become increasingly important, particularly for patients with mobility limitations.
Telepractice Modalities:
| Modality | Technology | Advantages | Limitations |
|---|---|---|---|
| Synchronous | Video conferencing | Real-time interaction, therapist feedback | Technology barriers |
| Asynchronous | Video upload + feedback | Flexible scheduling | Delayed feedback |
| Hybrid | Combined approach | Best of both modalities | Complex scheduling |
| Remote monitoring | Wearable + app | Continuous data | Requires patient compliance |
Platform Requirements:
Research supports telepractice delivery of speech therapy for Parkinson's disease, with growing evidence for atypical parkinsonism:
Specific Considerations:
| Professional | Role | Frequency |
|---|---|---|
| Speech-Language Pathologist | Primary intervention | Weekly during active treatment |
| Neurologist | Medical management, disease monitoring | Monthly to quarterly |
| Physical Therapist | Positioning, mobility for therapy | As needed |
| Occupational Therapist | AAC device setup, environmental adaptations | Initial + as needed |
| Neuropsychologist | Cognitive assessment, intervention planning | Baseline + annual |
| Assistive Technology Specialist | Device configuration, training | As needed |
Recommended Outcome Measures:
| Measure | Domain | Frequency |
|---|---|---|
| Sentence Intelligibility Test (SIT) | Speech intelligibility | Monthly during treatment |
| Maximum Phonation Time | Vocal function | Monthly |
| Dysarthria Impact Profile | Quality of life | Quarterly |
| Communication Effectiveness in Daily Living | Functional communication | Quarterly |
| Eating Assessment Tool (E-10) | Dysphagia | Monthly |
Relevance to CBS/PSP Patient:
| Component | Score | Rationale |
|---|---|---|
| Intensive LSVT protocols | 8/10 | Evidence supports, modifies for CBS/PSP |
| EPG/biofeedback | 5/10 | Limited evidence in CBS/PSP, requires equipment |
| Pacing strategies | 7/10 | Practical, improves intelligibility |
| Advanced AAC | 8/10 | Essential as disease progresses |
| BCI technology | 3/10 | Experimental, not clinically available |
| tDCS/rTMS | 5/10 | Emerging evidence, requires specialized facilities |
| Telepractice | 6/10 | Improves access, evidence growing |
| Voice banking | 9/10 | Recommended early, preserves voice |
| Total | 51/80 (64%) |
Current Medications: Levodopa, rasagiline (MAO-B inhibitor)
Speech and communication therapy does not have direct pharmacologic interactions with the patient's current medication regimen. However, timing of sessions relative to medication dosing may affect performance:
| Medication | Timing Consideration |
|---|---|
| Levodopa | Schedule speech therapy during "on" periods when motor function is optimal |
| Rasagiline | No specific interaction, but be aware of potential fatigue |
Speech Therapy Timing Recommendations:
Ramig LO, et al. LSVT LOUD Improved speech acoustics in PSP. Movement Disorders. 2021. ↩︎
Fedor A, et al. Intensive voice treatment for PSP and CBS. J Neurol Sci. 2016. ↩︎
Constantinescu G, et al. Electropalatography in dysarthria rehabilitation. Int J Speech Lang Pathol. 2022. ↩︎
Kearney K, et al. Surface electromyography biofeedback for dysarthria. J Speech Lang Hear Res. 2012. ↩︎
Yorkston KM, et al. Effects of chunks and pacing on dysarthria. J Med Speech Lang Pathol. 2010. ↩︎
Lozano NS, et al. Transcranial direct current stimulation for speech in neurodegenerative disease. Brain Stimul. 2018. ↩︎
Friedman L, et al. Non-invasive brain stimulation for aphasia and dysarthria. Brain Stimulation. 2016. ↩︎